Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 8/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | ATR | Q13535 | 2/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | USP7 | Q93009 | 1/20 | 0.44 |
| ▸ | NEK2 | P51955 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696482 | 0.87 | PIK3CG (0.55) | PIK3CGADORA2AADORA1ATRPRKDC | |
| SCHEMBL934795 | 0.81 | ADORA1 (0.56) | PIK3CGADORA2AADORA1ATRPRKDC | |
| SCHEMBL6701889 | 0.81 | ADORA1 (0.56) | PIK3CGADORA2AADORA1ATRPRKDC | |
| SCHEMBL934749 | 0.77 | ATR (0.52) | PIK3CGATRPRKDCATMBCHE | |
| SCHEMBL2931488 | 0.77 | NEK2 (0.64) | PIK3CGATRPRKDCATMNEK2 | |
| SCHEMBL12225269 | 0.74 | PIK3CG (0.55) | PIK3CGATRPRKDCATMBCHE | |
| SCHEMBL934746 | 0.72 | MAPT (0.51) | PIK3CGATRPRKDCATMBCHE | |
| SCHEMBL2933169 | 0.72 | ATR (0.63) | ATRPRKDCATMNEK2 | |
| SCHEMBL2936756 | 0.72 | ATR (0.62) | ATR | |
| SCHEMBL23064157 | 0.72 | PIK3CG (0.54) | PIK3CGATRPRKDCATMBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | UNIVERSITY CATHOLIQUE DE LOUVAIN (BE) | 2004-02-19 | — | — | US | claimed |
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | UNIVERSITY CATHOLIQUE DE LOUVAIN (BE) | 2004-02-19 | — | — | US | disclosed |
| EP-1292580-A1 | PYRAZINE AND IMIDAZOPYRAZINE DERIVATIVES AS ANTIOXIDANTS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001087853-A1 | ARYL-SUBSTITUTED N,N-HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS AND DIAGNOSTICS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | NOX5, NOX4, CD22 | PIK3CG 3785/4885ALOX5 249/4885ADORA2A 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.